OR WAIT null SECS
Tuzistra XR for cough relief is said to be the only twice-daily, extended-release codeine-based cough and cold syrup available in the US.
Vernalis and Tris Pharma announced that Tuzistra XR (codeine polistirex and chlorpheniramine polistirex), extended-release oral suspension, CIII (DEA Schedule III) is now available to patients and physicians in the United States.
FDA approved the extended-release formulation in April 2015 for the relief of cough, common cold, and symptoms associated with upper respiratory allergies in adults. Tuzistra XR is said to be the only codeine-based extended-release cough cold syrup available in the US.
The US cough cold prescription market has been valued at more than $3 billion, with 30–35 million annual prescriptions. This market is dominated by short-acting treatments, which require dosing four to six times a day.
Tuzistra XR was developed using Tris Pharma's liquid sustained release technology, LiquiXR, which allows for extended drug delivery throughout a 12-hour dosing period.